VGXI Inc. Presents Issues Related to High Concentration, Multi-Component Plasmid Products at the American Society of Gene Therapy 12th Annual Meeting

San Diego, CA – May 26, 2009 –


VGXI Inc., a leading manufacturer of DNA plasmids and creator of AIRMIXTM Technology, announced today that the company will present at the 2009 American Society of Gene Therapy 12th Annual Meeting at the San Diego Convention Center. The American Society of Gene Therapy (ASGT) is a non-profit medical, scientific, and professional organization devoted to the research and development of therapies that involve the introduction of genetic material and/or cells into the body to treat or prevent disease.

Henry Hebel, COO, will present at the ASGT 12th Annual Meeting and was quoted as saying, “The recent H1N1 outbreak illustrates the need to develop innovative vaccine technology capable of producing strain specific vaccines within a matter of weeks, rather than months. VGXI Inc. is routinely manufacturing multi-component strain specific vaccines for our clients at large scale and is capable of producing several hundred thousand doses per week, if required.”

VGXI Inc. will present the science behind the formulation and stability of high concentration, multi-component plasmid products. Multi-component DNA vaccines are increasing in demand in the advancing market which, consequently, poses challenges in production, formulation, stability and release testing. Extremely pure product is required to achieve high concentrations and is critical for accurate vaccine blending. This presentation will focus on the special considerations that must be made when developing this new class of products.

About VGXI Inc.
VGXI Inc. is a leading provider of DNA plasmid manufacturing and development services for DNA vaccine and gene therapy research. The Company has an outstanding track record of success in manufacturing plasmid products under cGMP conditions for client companies’ clinical studies in the US and Europe, and its cGMP and non-cGMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. The recently announced research and pre-clinical production services extend the range of high-quality, research grade materials utilizing the same efficient service. This rapid turnaround program provides consistent materials to build a reliable pre-clinical dataset.

Cautionary Factors That May Affect Future Results
Materials in this Web site contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

Company Contact:
Henry Hebel
Chief Operating Officer
Tel. 281.296.7300
Fax 281.296.7333
E-mail: hhebel@vgxii.com
www.vgxii.com